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1. Introduction  
Obesity rates are increasing worldwide. Free fatty acids derived from visceral adipose tissue 
impair insulin sensitivity and ǃ-cell function (lipo-toxicity), leading to the metabolic 
syndrome and type 2 diabetes. 
Weight loss is the cornerstone for diabetes prevention and treatment, thus lifestyle and 
eventually pharmacological interventions that achieve significant weight loss are widely 
accepted. Nevertheless, long-term compliance to diet and exercise as well as safety and 
efficacy concerns regarding obesity drugs limit their benefits in real world. Moreover, weight 
gain is a common and undesirable side-effect of several oral antidiabetic drugs and insulins. 
Bariatric surgery has demonstrated to be an effective and safe treatment option for type 2 
diabetic patients who are severely obese, what is linked to weight loss and other 
mechanisms. Considering weight loss-independent mechanisms for diabetes improvement, 
investigators in several countries have started mostly metabolic than bariatric procedures 
for mildly obese or even overweight patients, focused on diabetes rather than obesity, and 
their early results have been encouraging.  
1.1 Obesity and type 2 diabetes 
Obesity is and its related metabolic disorders are increasing worldwide, especially in 
developing countries in western hemisphere (Ford & Mokdad, 2008). In most cases, an 
increase in body mass index (BMI) reflects an underlying increase in body fat that leads to 
diabetes, hypertension and dyslipidaemia (Bays, 2009), cardiovascular risk factors that are 
associated with increased mortality (Berrington et al, 2010).  
Cardiometabolic risk increases not only with BMI, but waist circumference as well (National 
Institutes of Health [NIH], 1998). Waist circumference correlates tightly with visceral 
adipose tissue, and currently is a widely accepted assessment of the accumulation of 
intraabdominal or visceral adiposity (Despres et al, 2001).  
Visceral adipose tissue is more likely to be related to insulin resistance than subcutaneous 
adipose tissue (Banerji et al, 1997, as cited in Zinman, 2006). Visceral obesity-derived 
cardiometabolic risk factors are frequently linked to insulin resistance and tend to cluster, 
what is clinically recognised as the metabolic syndrome (Alberti et al, 2009).  
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These factors follow a common and progressive course, so the prevalence of metabolic 
syndrome is 10 to 15% in normoglycaemic individuals, 44 to 64% in prediabetic, and 78 to 
84% in type 2 diabetic patients (Isomaa et al, 2001). In other words, the more 
hyperglycaemic, the more dysmetabolic the individual will be. 
Metabolic and ultimately cardiovascular complications of visceral obesity are summarised 
in Figure 1.  
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Fig. 1. Cardiometabolic risk derived from visceral obesity. 
Visceral adipose tissue shows a high lipolytic activity, releasing free fatty acids (FFAs) to 
portal and then systemic circulation (Wajchenberg, 2000). FFAs, as well as cytokines and 
tumor necrosis factor-ǂ (TNF-ǂ), both derived from visceral adipose tissue, impair insulin 
action at target cells in liver and muscle, causing a postbinding defect that blocks tyrosine 
kinase activity,1 uncoupling insulin signal transduction (Le Roith & Zick, 2001). Insulin 
resistance is a key factor for the development of non-alcoholic fatty liver disease (NAFLD), 
and atherogenic dyslipidaemia.  
Insulin resistance is followed by pancreatic ǃ-cell compensation and hyperinsulinaemia, due 
to fuel and neurohormonal signals derived from fat, liver, intestine, and brain (Prentki, 
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2006). Hyperinsulinaemia stimulates sodium reabsortion at kidneys, as well as sympathetic 
nervous system activity, leading to vasoconstriction and enhanced cardiac output, 
increasing blood pressure (Reaven et al, 1996). In addition, hyperinsulinaemia exerts anti-
lipolytic and lipogenic actions, thus maintaining and increasing visceral adipose tissue 
(Wajchenberg, 2000).   
Nevertheless, while FFAs are one of the ǃ-cell compensation signals, they can cause ultimately 
ǃ-cell apoptosis, leading to prediabetic states and type 2 diabetes (Bell, 2003; Kasuga, 2006).  
Prediabetes (impaired fasting glucose and/or impaired glucose tolerance), in other words, 
slightly elevated plasma glucose levels, accelerates pancreatic failure through gluco-toxicity. 
1.2 Weight loss in diabetes prevention and treatment 
Weight loss is the cornerstone for diabetes prevention and treatment, thus lifestyle and 
eventually pharmacological interventions that achieve significant weight loss are widely 
accepted.  
1.2.1 Lifestyle intervention in diabetes prevention 
Modest weight loss, as part of a comprehensive intervention in lifestyle, has demonstrated 
significant reductions in the incidence of diabetes in high risk populations. In the Finnish 
Diabetes Prevention Study the intervention group showed a greater lose of weight when 
compared with a control group (weight reduction >5% in 43 versus 13% of the subjects, 
respectively), with a risk of type 2 diabetes reduced by 58% at 3.2 years (Tuomilehto et al, 
2001). In the American Diabetes Prevention Program, the average weight loss in the lifestyle 
intervention group was 5.6 kg compared with 0.1 kg in the placebo group, with a risk of 
type 2 diabetes reduced by 58% at 2.8 years (Diabetes Prevention Program [DPP] Research 
Group, 2002). In the Indian Diabetes Prevention Programme, the lifestyle modification 
group reduced their risk of type 2 diabetes by 28.5% at 2.5 years compared with the control 
group, without loosing weight (Ramachandran et al, 2006). 
1.2.2 Pharmacologic Interventions in diabetes prevention 
Weight loss and antidiabetic drugs have been tested in the prevention of type 2 diabetes. 
Orlistat, a gastrointestinal lipase inhibitor used in the treatment of overweight and obesity, 
showed a 37.3% reduction in diabetes incidence at 4 years in obese subjects (Torgerson et al, 
2004). Acarbose, an enteric -glycosidase inhibitor used in the treatment of type 2 diabetes, 
reduced diabetes incidence by 25% at 3.3 years in subjects with impaired glucose tolerance 
(Chiasson et al, 2002). Another antidiabetic drug, metformin, which enhances insulin 
sensitivity at liver and muscle tissues, showed a 31% reduction in diabetes incidence at 2.8 
years (DPP Research Group, 2002).  
Two effective obesity drugs, rimonabant and sibutramine, have been recently withdrawn in 
several countries because long-term safety concerns. 
1.2.3 Lifestyle intervention in diabetes treatment 
One-year results of the ongoing Look-AHEAD clinical trial, which is intended to assess 
whether intensive lifestyle intervention decreases major cardiovascular events in type 2 
www.intechopen.com
 
Advanced Bariatric and Metabolic Surgery 
 
266 
diabetic subjects, showed a significant weight reduction with lifestyle intervention when 
compared with a control group (-8.6 vs. -0.7%, respectively). Diabetes control and other 
cardiovascular disease risk factors were also improved, with reduced medicine use (Pi-
Sunyer et al, 2007).    
Long-term compliance to diet and exercise could be a major issue in clinical practice. In 
addition, weight gain is a common and undesirable side-effect of several oral antidiabetic 
drugs and insulins (Turner et al, 1998; Kahn et al, 2006). 
2. Diabetes improvement following weight loss surgery   
Currently accepted indications for bariatric surgery are BMI 40 kg/m2 or BMI 35 kg/m2 
when comorbidities are associated (NIH, 1998). Bariatric surgery has demonstrated significant 
weight reduction, and improvement on cardiometabolic risk factors such as type 2 diabetes 
mellitus, dyslipidaemia, and hypertension, in severely obese patients. Moreover, this 
procedures are associated with 29% decreased overall mortality at 15-year follow-up (Sjostrom 
et al, 2007). Because the improvement observed not only in excess weight reduction, but in 
cardiometabolic risk factors as well, these procedures have been recently recognised as 
“bariatric and metabolic”. Principal mechanisms leading to diabetes and metabolic 
improvement following bariatric and metabolic procedures are summarised in Table 1. 
 
MECHANISM CLINICAL BENEFIT 
Decreased Lipo-toxicity (weight loss) Improved metabolic syndrome 
Decreased  ghrelin and increased PYY Decreased appetite and increased satiety 
Enhanced incretin effect Improved diabetes control 
Table 1. Main mechanisms for diabetes and metabolic improvement following surgery.  
2.1 Decreased lipo-toxicity 
Diabetes remission, defined as fasting plasma glucose <126 mg/dL (7.0 mmol/L) without 
hypoglycaemic therapy, occurs in 72 and 36% at two an ten years respectively in surgical 
patients, compared with 21 and 13% in conventionally treated subjects. On the other hand, 
diabetes incidence in non-diabetics is 1 and 8% at two and ten years respectively in the 
surgical group compared with 8 and 24% in the control group (Sjostrom et al, 2004, as cited 
in Dixon et al, 2011).  
Undoubtedly, such metabolic benefit is closely related to weight loss because a marked 
reduction in FFA-derived lipo-toxicity. Lipo-toxicity impairs insulin action at target tissues 
and increases pancreatic ǃ-cell apoptosis. One randomised controlled trial that compared 
laparoscopic adjustable gastric banding (LAGB), a pure restrictive technique, versus 
comprehensive medical therapy for obese type 2 diabetic individuals showed a significant 
5.5-fold higher remission at two years in the surgical group (Dixon et al, 2008). In this 
regard, procedures that achieve weight loss and decrease lipo-toxicity should be viewed as 
“metabolic”.  
2.2 Weight loss-independent mechanisms for diabetes control 
Bypass or malabsortive procedures appear to result in greater metabolic benefit than 
restrictive ones, and a common observation is that diabetes remission is achieved within 
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days to weeks of undergoing surgery, before significant weight loss has occurred (Pories et 
al, 1995). These facts lead to conclude that additional and, at some extent, weight loss-
independent mechanisms are involved. These mechanisms, thus more metabolic than 
bariatric, could be summarised as reduced caloric intake and enhanced incretin effect 
(Lahsen & Berry, 2010). 
2.2.1 Reduced caloric intake  
Gastrointestinal hormones and peptides involved in the regulation of energy homeostasis 
may be modified following bariatric surgery. Roux-en-Y Gastric Bypass (RYGB) and Sleeve 
Gastrectomy (SG) increase peptide YY (PYY) (Morinigo et al, 2006) and reduce ghrelin levels 
(Cummings et al, 2002, Karamanakos et al, 2008). PYY is an appetite suppressant peptide 
secreted by distal ileum and colon, whereas ghrelin is an orexigenic hormone secreted by 
gastric fundus. Thus, post surgery changes in gut-derived hormones result in decreased 
appetite and increased satiety, which enhance patients’ compliance to lifestyle intervention 
guidance.   
2.2.2 Incretin effect  
Food intake is followed by the release of several intestinal peptides, some of which increase 
insulin levels. The increase in insulin secretion is higher after oral or enteral glucose 
ingestion when compared to intravenous administration, what is called the incretin effect. 
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) are 
the two most studied peptides, being GLP-1 probably the most important in terms of 
carbohydrate homeostasis. GLP-1 secretion from L-cells at the ileum rises after a meal and 
enhances insulin biosynthesis and release by pancreatic ǃ-cells, decreases glucagon release 
by pancreatic -cells, improves glucose uptake and glycogen synthesis in liver and 
peripheral tissues, slows gastric emptying, and decreases appetite and increases satiety at 
central nervous system. GIP is released from K-cells in duodenum, and stimulates post-meal 
insulin secretion and promotes ǃ-cell mass expansion (Drucker, 2003). Type 2 diabetes is 
associated with a reduced or lost incretin effect that contributes with impaired insulin 
secretion (Toft-Nielsen et al, 2001). Bariatric surgery, especially RYGB, significantly 
enhances GLP-1 levels and activity in severely obese subjects with or without diabetes 
(Laferrere et al, 2007). 
3. Metabolic surgery in non-severely obese type 2 diabetics 
Theoretically, it could be plausible the design of surgical techniques focused mainly on 
weight loss, caloric intake, or incretin effect, depending on patients’ individual needs and 
careful clinical judgment. 
3.1 Duodenal-Jejunal bypass and the Hindgut and Foregut hypothesis 
Experimental studies were performed in non-obese diabetic rats, who underwent duodenal-
jejunal bypass (DJB), a stomach-preserving RYGB that excludes proximal intestine, or 
gastrojejunostomy (GJ), which creates a shortcut for ingested nutrients without bypassing 
intestine (Rubino et al, 2006). No differences in body weight, food intake, or nutrient 
absorption were observed between surgical groups, however DJB-treated rats improved 
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their oral glucose tolerance. When GJ rats were reoperated to exclude proximal intestine a 
marked improvement in oral glucose tolerance was observed and, conversely, restoration of 
duodenal passage in DJB rats impaired oral glucose tolerance. In this study, Rubino 
demonstrated that bypassing proximal intestine directly ameliorates diabetes by weight 
loss-independent mechanisms. 
At some extent, two theories are born. The “hindgut hypothesis”, is explained by the rapid 
nutrient delivery to distal intestine that enhance the secretion of GLP-1, PYY, and 
oxyntomodulin, which are involved in the reduction of food intake and gastrointestinal 
motility, and improvement in glucose homeostasis. The second theory, the “foregut 
hypothesis” or duodenal exclusion, clearly demonstrates that duodenum and proximal 
jejunum bypass of nutrients plays a major role in diabetes resolution.  
3.2 Rationale for metabolic surgery in diabetic patients with BMI <35 kg/m
2
 
The American Diabetes Association established for first time in 2009 that bariatric 
procedures should be considered for diabetic adults with BMI ≥35 kg/m2 when diabetes is 
poor controlled with lifestyle and pharmacologic therapy. American Diabetes Association 
does not recommend surgery in patients with BMI <35 kg/m2 outside a research protocol 
(American Diabetes Association, 2009). Nevertheless, and as observed in landmark diabetes 
clinical trials, most type 2 diabetic individuals are overweight or mildly obese, with a BMI 
close to 30 kg/m2, below the cut-off for eligibility in current guidelines, disregarding the 
presence of a visceral pattern of obesity (Lahsen & Berry, 2010). Precisely, type 2 diabetic 
individuals having the metabolic syndrome have a very high risk of cardiovascular 
complications (Isomaa et al, 2001). Table 2 summarises the criteria followed by the authors 
to consider bariatric and metabolic surgery in type 2 diabetic subjects. 
 
BODY MASS INDEX (kg/m2) OBSERVATIONS 
 35 Consider surgery 
< 35 Consider surgery when metabolic syndrome is present 
< 30 Consider surgery only as part of a Clinical Research Protocol 
Table 2. Selection criteria for bariatric and metabolic surgery in type 2 diabetes. 
In recent years, several groups performing both established and novel surgical procedures 
in type 2 subjects with BMI <35 kg/m2 have shown encouraging metabolic results. It must 
be noted that these procedures should be performed as part of a clinical research protocol 
with local ethical approval. 
3.3 Clinical results of metabolic surgery  
Our group started a clinical research protocol assessing DJB in early 2008, and 19 non-obese 
(BMI <30 kg/m2) type 2 diabetic patients underwent surgery by late 2010. Our preliminary 
metabolic results are encouraging, however surgical technique modifications have been 
done due to concerns regarding gastroparesis, a previously reported surgery-derived 
adverse effect on gastric emptying. This issue was handled performing a non-restrictive SG, 
turning DJB into a modified duodenal switch, a well known procedure with proven benefits 
on glucose metabolism. The authors have seen better results, less morbidity (no 
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gastroparesis) and a better metabolic control with diabetes remission in near 75% of the 
cases, what was presented at the XIV Latin American Diabetes Association Congress held in 
Santiago, Chile, in november 2010 (Table 3).  
 
Variable Pre-Surgery Post-Surgery P* 
BMI, kg/m2 27.7 25.3 <0.001 
Fasting plasma 
glucose, mg/dL 
(mmol/L) 
163                 
(9.1) 
131                 
(7.3) 
0.01 
HbA1c, % 8.3 6.7 <0.001 
Patients with HbA1c 
<7%, % 
26.3 73.60 0.05** 
Pharmacologic treatment (n) 
None 0 6  
Oral monotherapy 2 9  
Oral combination 
therapy 
15 3  
Insulin 2 1  
* T test; ** Fisher test. 
Table 3. Clinical results of Modified Duodenal-Jejunal Bypass in 19 non-obese type 2 
diabetic patients.  
But, Why to perform “the most aggressive” surgery in non-obese patients? What about their 
weight loss? To answer the first question it must be considered the almost pure hormonal 
effect that is achieved in this subset of patients, where weight loss is not the “common 
factor” observed in restrictive and malabsortive bariatric procedures. Answering the second 
question requires considering that obese patients with different degree of severity who 
undergo the same surgery lose almost the same excess weight proportion, what can be 
explained as an “accommodation” of the caloric intake to the metabolism “real 
requirements”. Our patients, with BMI between 25 and 30 kg/m2, experienced a moderated 
lose of weight during the first 12 weeks after surgery, recovering later their inicial weight or 
maintaining BMI close to 25 kg/m2, with no excessive weight loss. This fact was also noted 
by Scopinaro, who performed a novel surgical procedure in type 2 diabetic individuals with 
BMI <35 kg/m2, achieving metabolic control and moderated weight loss (Scopinaro et al, 
2007). 
3.4 Novel metabolic procedures  
Clinical researchers worldwide are performing novel surgical and endoscopic procedures 
and assessing their metabolic and surgical long-term efficacy and safety.   
3.4.1 Sleeve gastrectomy 
While SG is considered a pure restrictive technique, it is noteworthy that weight loss-
mediated decrease in lipo-toxicity is metabolic per se, and SG reduces ghrelin, increases 
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peptide YY, and increases GLP-1 (Peterli et al, 2009), so SG must be viewed as metabolic 
surgery as well. We have assessed clinical and metabolic results in obese patients with easily 
controlled or recently diagnosed diabetes, which underwent SG with promising results: 
remission of the disease, no medication longer required, and very low morbidity rates.  
3.4.2 Endobarrier
®
 
One of the non invasive metabolic procedures currently under investigation is the 
“Endobarrier®”, a polypropylene sleeve endoscopically installed, anchored to the pylorus, 
that extends until the first portion of the jejunum. Its mechanism of action is the isolation of 
the food from the pancreatic enzymes and bile. This device has to be removed at 12 month, 
while an acceptable glycaemic control has been observed, and early results in obese patients 
also shows a moderated weight loss. 
4. Current and future indications for metabolic surgery 
Current obesity guidelines consider surgery when type 2 diabetes is associated with BMI 
≥35 kg/m2, however diabetes guidelines have incorporated surgical options very recently. 
In 2009 the American Diabetes Association established that bariatric surgery should be 
considered for diabetic adults with BMI ≥35 kg/m2 if metabolic control is difficult to achieve 
with lifestyle and pharmacological therapy. In March 2011 the International Diabetes 
Federation released a position paper which considers with some restrictions bariatric 
surgery for type 2 diabetic patients with BMI ≥30 kg/m2, and historically, for first time 
includes bariatric surgery in a diabetes treatment algorithm. 
Probably future guidelines will consider not only BMI but also waist circumference and 
other elements of the metabolic syndrome as well as the presence and extent of diabetic 
chronic complications, patients’ preference and quality of life. 
5. Conclusions 
Bariatric surgery has demonstrated to be an effective and safe therapy for obesity in subjects 
with BMI ≥40 kg/m2, and in type 2 diabetic patients with BMI ≥35 kg/m2. 
The major factor involved in metabolic improvement after surgery is weight loss, which 
decreases lipo-toxicity. Any procedure that achieves weight loss must be recognised as 
metabolic. 
There are weight loss-independent mechanisms for metabolic improvement that can be 
summarised as decreased appetite and increased satiety, due to post surgical changes in 
ghrelin and PYY, and enhanced ǃ-cell function, due to an increased incretin effect. 
Novel surgical techniques have been developed in recent years, aimed to correct 
dysmetabolism through weight loss-independent mechanisms in type 2 diabetic patients 
who are mildly obese or even overweight, with promissory early results. 
Nowadays, these procedures have been part of clinical investigation protocols approved by 
each local ethics committee.  
Future indications for metabolic procedures will consider other factors than BMI. 
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